Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Sees Large Decrease in Short Interest

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) was the target of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 9,400 shares, a decrease of 15.3% from the March 31st total of 11,100 shares. Based on an average daily volume of 31,300 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.1% of the company’s stock are short sold.

Sol-Gel Technologies Stock Performance

Shares of SLGL opened at $0.89 on Monday. The stock has a market cap of $24.78 million, a PE ratio of -0.88 and a beta of 1.33. Sol-Gel Technologies has a fifty-two week low of $0.79 and a fifty-two week high of $4.05. The firm’s 50-day simple moving average is $1.01 and its two-hundred day simple moving average is $1.19.

Sol-Gel Technologies (NASDAQ:SLGL) last announced its quarterly earnings data on Wednesday, March 13th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The business had revenue of $0.45 million during the quarter, compared to analysts’ expectations of $0.27 million. Sol-Gel Technologies had a negative return on equity of 61.52% and a negative net margin of 1,331.01%. Equities research analysts predict that Sol-Gel Technologies will post -0.67 EPS for the current year.

Institutional Investors Weigh In On Sol-Gel Technologies

An institutional investor recently bought a new position in Sol-Gel Technologies stock. Yelin Lapidot Holdings Management Ltd. purchased a new stake in shares of Sol-Gel Technologies Ltd. (NASDAQ:SLGL) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 229,178 shares of the company’s stock, valued at approximately $374,000. Yelin Lapidot Holdings Management Ltd. owned about 0.99% of Sol-Gel Technologies as of its most recent SEC filing. 26.18% of the stock is owned by institutional investors and hedge funds.

Sol-Gel Technologies Company Profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.